BCYC · Bicycle Therapeutics PLC
$4.14
+0.15 (+3.76%)
At close · Aug 19
Market Cap
$279.27M
Shares
69.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.14
Open$4.05
Day$4.03–4.16
52W close$3.86–8.87
Avg vol 30d328K
Short int3.0M · 4.3% float · 9.9d
Short vol28%
Last earningsOct 30, 2025
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
+1%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
6%
near low
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−27%
trailing
YTD return
−42%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.26% of float · ▲ +0.0% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
104 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+106%
Y/Y
EPS growth
−9%
Y/Y
Free cash flow
$-252.0M
Balance sheet
$597.4M
net cash
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$54.4K over 90 days · 100% sells
Short interest
Rising
4.26% of float · ▲ +0.0% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
104 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 6%
Range high $9
vs 200-day avg -22%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCYC
this stock
Bicycle Therapeutics PLC
|
$279.27M | -41.5% | +105.8% | — | 4.3% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCYC | +2.0% | -1.7% | -26.6% | +7.3% | -41.5% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.4% | -4.6% | -38.2% | +4.3% | -54.3% |
Key facts
CIK
1761612
CUSIP
088786108
13F (30d)
99 filings
98 filers
Visit website
Investor relations